SAN DIEGO , March 28, 2017 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, today announced that it has entered into securities purchase agreements with certain
SAN DIEGO , March 2, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today
SAN DIEGO , March 15, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has
SAN DIEGO , Feb. 8, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock and warrants to purchase up to
SAN DIEGO , March 5, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today
SAN DIEGO --(BUSINESS WIRE)--May 24, 2023-- Biocept, Inc . (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces the pricing of an underwritten public offering of 1,176,470 shares of its common stock (or pre-funded warrants
SAN DIEGO , Sept. 21, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has
SAN DIEGO , Jan. 18, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has
SAN DIEGO , Jan. 26, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces
SAN DIEGO , April 14, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today
